Patient Care

The Division of Malignant Hematology and Medical Oncology provides inpatient consultative care across four UPMC facilities: Shadyside, Presbyterian, Montefiore, and Magee-Womens Hospital. At UPMC Shadyside, dedicated inpatient services include general oncology, a bone marrow transplant service, and an acute leukemia service. Outpatient care is delivered through fully staffed clinics at the Hillman Cancer Center and Magee-Womens Hospital. Beyond routine care, these sites serve as major hubs for clinical and translational research, including the conduct of therapeutic trials.

Cancer Treatment

Internationally recognized for its expertise in the prevention, detection, diagnosis, and treatment of cancer, the Division works in close partnership with UPMC Hillman Cancer Center (HCC), the region’s only NCI-designated Comprehensive Cancer Center. Together, we are committed to delivering the highest standards of cancer care and advancing innovative therapies for all cancer types.

Our physicians follow standardized, evidence-based clinical pathways supported by web-based decision tools to tailor treatment plans to each patient’s cancer type and stage. These pathways integrate the most effective standard-of-care therapies with promising clinical trial opportunities. HCC is also a national leader in immunotherapy, being the first center in western Pennsylvania to offer chimeric antigen receptor (CAR) T-cell therapy.
Patients have access to more than 400 active clinical trials, many of which are available at UPMC Hillman network sites, ensuring that leading-edge research and advanced care are accessible close to home. Through participation in multidisciplinary tumor boards and specialty conferences, our faculty collaborate across oncology disciplines to provide comprehensive, coordinated care, often allowing patients to meet with multiple oncology specialists in a single day.